OncoArendi Therapeutics – a biotechnology company specializing in the discovery, development and commercialization of innovative drugs, has hired Dr. Timi Oshodi as Director of Preclinical Development. Dr. Oshodi will be responsible for planning and implementing of preclinical safety and pharmacokinetic studies for molecules developed by the company.
Dr. Timi Oshodi has more than 25 years of experience working as a toxicologist in international contract research organizations (CROs) and biotechnology companies, including the Evotec Group and Envigo, where he managed a team of nearly 50 scientists. He holds a Ph.D. in pharmacology and has worked in senior management positions at several CRO across the globe, including Charles River Laboratories – one of the world’s leading companies in the industry. He was also an independent toxicology consultant in many pharmaceutical and biotechnology companies.
“We are very pleased that Timi, who has valuable international experience in the development of biotechnology projects in the pre-clinical stage, has joined OncoArendi. This is one of the key roles that will strengthen the new organizational structure in the company. Timi will support all of our most advanced projects in preparation for clinical trials, as well as the selection of further drug candidates within the chitinase platform and the development of deubiquitinase inhibitors – says Rafał Kamiński, Chief Scientific Officer of OncoArendi Therapeutics.